RECENT COMMENTS

Rajesh Kumar: Is it helpfull for Overian cancer patient at advance stage? Rajesh Kumar +919681303310   »Read more

Cindy: I'm not a medical professional. My mother has been diagnosed with CUP - and was treated several year [...]   »Read more

Rajesh Kumar: +919681303310.   »Read more

Rajesh Kumar: Please write your comment here   »Read more

christian: Is gabapentin has been proposed to treat peripheric neuropathy induced by chemotherapy. At low dosa [...]   »Read more

Patient Voice


Issue 35
Spreading the word
Issue 34
Shall we try for a baby?
Issue 32
A man with a woman's cancer: How can we do better for male breast cancer patients?
Issue 29
Emaciated by not unloved: Patients and carers need support to cope with distressing effects of cachexia
Issue 26
Why 'plenty of bed rest' could be bad advice
Issue 25
Europe must tackle health illiteracy to avoid a health 'underclass'
Issue 24
Protection of employment rights: still work in progress
Issue 23
It's not just about surviving, it's about getting your life back
Issue 22
Surviving childhood cancer
Issue 20
Don't look away
Issue 19
Living with the consequences
Issue 18
Neither child nor adult
Issue 17
No one told me I had a choice
Issue 14
Take one at bedtime and you'll soon feel worse
Issue 11
When clinical trials are compromised
Issue 9
The news is bad...the message maybe worse
Issue 9
When alternative becomes mainstream
Issue 7
Fertility: it's up to the doctors to think ahead
Issue 5
Look - no strings!
Issue 3
Just the job? It's time to try out the new disability rights laws
Issue 2
Talk to me not to your feet
Issue 1
Nothing about us without us

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR16 - Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists (based on a review article of Critical Reviews in Oncology Hematology)

GR182 - Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

GR183 - The current management of low-grade glioma in childhood

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.